معرفی
Dr. Mary Fidler is a Professor in the Department of Oncology at Rush University Medical College. Her work focuses on clinical oncology, particularly lung cancer therapies, immunotherapy outcomes, and biomarker-driven treatment strategies. She has contributed to studies evaluating the impact of cachexia, chemotherapy, and immune checkpoint inhibitors in advanced cancers.
Her research spans clinical trials, molecular profiling, and translational oncology. Key areas include NSCLC treatment optimization, biomarker development (e.g., neutrophil-to-lymphocyte ratio), and the effects of comorbidities like cachexia. Dr. Fidler collaborates widely, with notable contributions to the TERAVOLT registry analyzing thoracic malignancies during the pandemic.
Publications highlight her work in J Thorac Oncol, Cancer, and Lancet, focusing on treatment efficacy, patient outcomes, and quality-of-life metrics. Her studies often address disparities in care, elderly populations, and immune-related adverse events.
